Choroidal neovascularization in pathological myopia

Progress in Retinal and Eye Research
Kumari NeelamTien Y Wong

Abstract

Myopic choroidal neovascularization (CNV) is one of the leading causes of visual impairment worldwide. The clinical and socioeconomic impact of myopic CNV in Asian countries is particularly significant due to rising trend in the prevalence and severity of pathological myopia. The exact pathogenesis of myopic CNV remains unclear and there is paucity of information with respect to incidence and risk factors for myopic CNV from prospective studies. Furthermore, there are no recognized measures that may prevent or delay the development of CNV in eyes with pathological myopia. Advances have been made in the diagnosis and characterization of myopic CNV over the years. Until recently, treatment modalities for myopic CNV were limited to thermal laser photocoagulation and photodynamic therapy with verteporfin, both these modalities primarily aim at prevention of further visual loss. In the last 5 years, inhibitors of vascular endothelial growth factor (VEGF) have been used successfully and may improve vision to some extent. Nevertheless, the long-term safety and efficacy of anti-VEGF agents remains unknown. Furthermore, the risk of developing chorioretinal atrophy remains the key factor in determining the final visual outcome. This revi...Continue Reading

References

May 1, 1979·Ophthalmology·B J Curtin
Jan 1, 1992·Retina·H E Grossniklaus, W R Green
Dec 1, 1984·Ophthalmology·M P AvilaC L Schepens
Aug 1, 1983·Ophthalmology·G R HamptonA C Bird
Sep 1, 1982·Ophthalmology·K G Noble, R E Carr
Nov 1, 1993·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·R Machemer, U H Steinhorst
Jul 15, 1993·American Journal of Ophthalmology·A F FercherH Sattmann
Aug 1, 1996·Ophthalmology·S Y CohenG J Coscas
Aug 1, 1996·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·A YoshidaM Kojima
Nov 1, 1996·American Journal of Ophthalmology·M QuarantaG Soubrane
Feb 20, 1999·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·U M NoskeH Diddens
Mar 10, 1999·Eye·M T BensonS Beatty
Nov 5, 1999·Survey of Ophthalmology·H Matsumura, H Hirai
Mar 18, 2000·Archives of Ophthalmology·A Uemura, M A Thomas
Apr 24, 2001·The British Journal of Ophthalmology·B SeetA S Lim
Apr 25, 2001·Biological Trace Element Research·X HuibiH Xiuxian
Jun 5, 2001·Current Opinion in Ophthalmology·M F ShulerA C Ho
Jun 5, 2001·Current Opinion in Ophthalmology·D G Miller, L J Singerman
Jun 29, 2001·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·H XuX Han
Jul 31, 2001·American Journal of Ophthalmology·M IchibeH Abe
Oct 9, 2001·American Journal of Ophthalmology·R A CostaJ A Cardillo
Mar 9, 2002·Retina·UNKNOWN Verteporfin Roundtable 2000 and 2001 ParticipantsUNKNOWN Verteporfin in photodynamic therapy (VIP) study group principal investigators
Mar 22, 2002·Acta Ophthalmologica Scandinavica·Takayuki BabaManabu Mochizuki
Apr 3, 2002·Ophthalmology·Jerry VongphanitJie Jin Wang
Apr 5, 2002·American Journal of Ophthalmology·Nadine HamelinGisèle Soubrane
Apr 17, 2002·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Yu-sheng WangPeter Wiedemann

❮ Previous
Next ❯

Citations

Oct 19, 2012·International Ophthalmology·Hui Yee NeoKah-Guan Au Eong
Mar 30, 2013·Optometry and Vision Science : Official Publication of the American Academy of Optometry·Qin LongYang Jiang
Apr 3, 2014·The British Journal of Ophthalmology·Susumu SakimotoKohji Nishida
Jun 29, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Emma D Deeks
Mar 4, 2014·Expert Review of Clinical Pharmacology·Bozho TodorichPaul Hahn
Dec 17, 2015·Expert Opinion on Biological Therapy·Marion R MunkSebastian Wolf
Oct 7, 2014·Expert Opinion on Biological Therapy·Saba HashemiMohammad Abdollahi
Feb 24, 2016·Archivos de la Sociedad Española de Oftalmología·J M Ruiz-MorenoUNKNOWN en representación del grupo del estudio Mypathway
Nov 13, 2015·Orphanet Journal of Rare Diseases·Louise F PorterGraeme C Black
Jan 16, 2016·Progress in Retinal and Eye Research·Kyoko Ohno-MatsuiChiu Ming Gemmy Cheung
Jun 14, 2014·Seminars in Ophthalmology·Alexander K SchusterUrs Vossmerbaeumer
Mar 26, 2015·Experimental Eye Research·Xiangjia ZhuYi Lu
Apr 22, 2015·Saudi Journal of Ophthalmology : Official Journal of the Saudi Ophthalmological Society·M LoutfiA Kamal
Oct 22, 2014·Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)·Victor KohAudrey Chia
Mar 10, 2015·Ophthalmology·Yasushi IkunoUNKNOWN MYRROR Investigators
Jan 31, 2015·American Journal of Ophthalmology·Kyoko Ohno-MatsuiUNKNOWN META-analysis for Pathologic Myopia (META-PM) Study Group
Jul 6, 2014·The British Journal of Ophthalmology·Tien Y WongAdnan Tufail
Jul 14, 2014·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Claudio TraversiGian Marco Tosi
May 20, 2016·Acta Ophthalmologica·Preeti GuptaChing-Yu Cheng
Jul 2, 2016·Drugs·Kelvin Yi Chong TeoChui Ming Gemmy Cheung
Nov 30, 2016·Asia-Pacific Journal of Ophthalmology·Kyoko Ohno-Matsui
Jul 12, 2017·Clinical & Experimental Optometry : Journal of the Australian Optometrical Association·Monica JongMingguang He
Mar 10, 2018·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·UNKNOWN Berufsverband der Augenärzte Deutschlands e. V. (BVA)UNKNOWN Retinologische Gesellschaft e. V. (RG)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Autoimmune Polyendocrinopathies

Autoimmune polyendocrinopathies, also called polyglandular autoimmune syndromes (PGASs), or polyendocrine autoimmune syndromes(PASs), are a heterogeneous group of rare diseases characterized by autoimmune activity against more than one endocrine organ, although non-endocrine organs can be affected. Discover the latest research on autoimmune polyendocrinopathies here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.